Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TME Pharma NVXPAR:ALTME +0.32% 14-Day RSI is 40.93 as of Aug. 07, 2026. The stock has 4 warning signs investors should review. Among 1,421 Biotechnology companies, TME Pharma NV ranks better than 81% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-07), TME Pharma NV's 14-Day RSI is 40.93.
The industry rank for TME Pharma NV's 14-Day RSI or its related term are showing as below:
XPAR:ALTME's 14-Day RSI is ranked better than 81% of 1421
companies
in the Biotechnology industry
Industry Median: 48.78
vs XPAR:ALTME: 40.93
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
TME Pharma NV 14-Day RSI Related Terms
XPAR:ALTME vs VRTX, REGN, RVMD: 14-Day RSI Comparison
For the Biotechnology subindustry, TME Pharma NV's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TME Pharma NV 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TME Pharma NV's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where TME Pharma NV's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TME Pharma NV (XPAR:ALTME) has a 14-Day RSI of 40.93 as of Aug. 07, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on TME Pharma NV and its competitors. According to the industry distribution chart, TME Pharma NV ranks #270 out of 1421 companies in the Biotechnology industry, placing it in the top 19%.
Is TME Pharma NV's 14-Day RSI too high?
TME Pharma NV's current 14-Day RSI is 40.93. The Biotechnology industry median 14-Day RSI is 48.78. TME Pharma NV's value of 40.93 is 16.1% below this industry median. Based on the distribution chart, TME Pharma NV ranks #270 out of 1421 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does TME Pharma NV's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TME Pharma NV ranks #270 out of 1421 companies for 14-Day RSI. This places TME Pharma NV in the top 19% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 48.78. TME Pharma NV's value of 40.93 is 16.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.78, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TME Pharma NV's current 14-Day RSI of 40.93 is 16.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on TME Pharma NV and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TME Pharma NV's current 14-Day RSI is 40.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current 14-Day RSI of 40.93. The current 14-Day RSI is 40.93 and 16.1% below the Biotechnology industry median of 48.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current 14-Day RSI is 40.93 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALTME has been successfully added to your 
